興發集團(600141.SH):黑磷的臨牀前研究工作目前正在穩步推進,預計今年底至明年上半年完成
格隆匯4月21日丨有投資者在投資者互動平台向興發集團(600141.SH)提問,“黑磷在醫藥產業應用推廣進度?”
興發集團回覆稱,公司與合作伙伴已經在細胞層面證實了黑磷的抗腫瘤作用,但還需要進行完整的藥效學和毒理學等系統研究。在完成上述臨牀前綜合研究之後,即可尋求與醫藥企業進行合作。黑磷的臨牀前研究工作目前正在穩步推進,預計今年底至明年上半年完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.